NL-OMON36196已完成不适用
A phase I, mono-center, randomized, placebo and comparator controlled, single blind, rising dose, clinical study to determine single dose pharmacokinetics, pharmacodynamics, safety and tolerability of four doses of FSH-GEX* according to adaptive design (25, 75, 150 and 300 IU) administered subcutaneously in healthy pituitary-suppressed female volunteers - GEXGP24101
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 18
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •Healthy female subjects
排除标准
- •Clinical significant abnormalities at screening
研究者
相似试验
已完成
不适用
Phase I, single-centre, randomised, placebo-controlled, double-blinded study, with single ascending dose and multiple dose at maximum tolerated dose, evaluating the safety, tolerability and pharmacokinetics of ALX-0171, administered by pulmonary inhalation, in healthy male volunteersvirus that infect the airwaysrespiratory syncytial virus infection1004743810024970NL-OMON37342Ablynx NV100
已完成
不适用
Phase I, Single-Center, Randomized, Placebo-Controlled, Double-Blinded Study with Single Ascending Doses, Evaluating the Safety and Tolerability of T20K, Administered by a 1-hr IV Infusion in Healthy Male VolunteersMultiple SclerosisNL-OMON48273Cyxone AB40
已完成
1 期
A Phase 1, Single-Center, Randomized, Placebo-Controlled, Ascending Single-Dose Study of the Pharmacokinetics, Safety, and Tolerability of Oral XG005 in Healthy VolunteersChronic PainACTRN12617001330336Xgene Pharmaceutical Inc.50
进行中（未招募）
1 期
A Phase I/II, randomised, multicentre, placebo-controlled, partially-blinded, parallel-group study to assess the safety, tolerability and immune response following vaccination with ImmunoseTM FLU in older adults (age 50 to 75 years)MedDRA version: 20.0 Level: PT Classification code 10022000 Term: Influenza System Organ Class: 10021881 - Infections and infestationsInfluenzaEUCTR2017-004376-64-SEEurocine Vaccines AB300
已完成
不适用
A Phase 1, Single-Center, Single-Blind, Placebo and Propofol Controlled Study in Healthy Subjects to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Ascending Intravenous (IV) Infusion Doses of ABP-700anesthesiaNL-OMON41980Annovation Biopharma, Inc. (a wholly owned subsidiary of The Medicines Company, Inc.)72